Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton s tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia.
Ibrutinib: a novel Bruton s tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
.
